7Indexed trials
drug · Product Intelligence
Semaglutide
Pipeline Intelligence
Semaglutide: 7 indexed trials, 4 sponsors; 26 linked Orange Book patents and 9 FDA-linked events where matched.
4Sponsors
26Orange Book patent links
9FDA-linked events
Development evidence
NCT03574597Novo Nordisk A/S · strokePHASE3
NCT04777409Novo Nordisk A/S · alzheimersPHASE3
NCT05514535Novo Nordisk A/S · out_of_scopePHASE3
NCT05567796Novo Nordisk A/S · out_of_scopePHASE3
NCT06045221Eli Lilly and Company · out_of_scopePHASE3
NCT06072963Rutgers, The State University of New Jersey · alzheimersPHASE2
NCT06639464Brigham and Women's Hospital · substance_usePHASE2
FDA / patent evidence
11318191WEGOVY · app 2152562041-02-17
11478533WEGOVY FLEXTOUCH · app 2152562040-05-13
11833248OZEMPIC · app 2130512039-02-01
12396953WEGOVY · app 2183162039-02-01
12396953OZEMPIC · app 2130512039-02-01
11833248WEGOVY · app 2183162039-02-01
12551536WEGOVY FLEXTOUCH · app 2152562038-10-10
12029779WEGOVY · app 2152562038-10-10
11752198WEGOVY · app 2152562038-08-24
12214017WEGOVY HD · app 2152562038-08-24
10888605WEGOVY · app 2152562038-08-24
12569543WEGOVY · app 2152562037-04-28
Regulatory context
FDA_EXCLUSIVITYWEGOVY HD · NS2029-03-19
FDA_EXCLUSIVITYWEGOVY · NP2028-12-22
FDA_EXCLUSIVITYRYBELSUS · I-9762028-10-17
FDA_EXCLUSIVITYWEGOVY FLEXTOUCH · I-9732028-08-15
FDA_EXCLUSIVITYWEGOVY FLEXTOUCH · I-9352027-03-08
FDA_EXCLUSIVITYWEGOVY · I-9352027-03-08
FDA_APPROVALWEGOVY FLEXTOUCH · 2026-06-18
FDA_APPROVALWEGOVY · 2025-12-22
FDA_APPROVALRYBELSUS · 2019-09-20
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.